Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling

被引：0
|
作者：
Liu, Stephanie N. [1 ]
Chan, Phyllis [1 ]
Marchand, Mathilde [2 ]
Herraez-Baranda, Luis [3 ]
Bruno, Rene [4 ]
Chanu, Pascal [5 ]
Wu, Benjamin [1 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Certara Strateg Consulting, Paris, France
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Genentech Roche, Marseille, France
[5] Genentech Roche, Lyon, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.99
引用
收藏
页码：E44 / E44
页数：1
相关论文
共 42 条
  • [41] IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Burotto, M.
    Zvirbule, Z.
    Alvarez, R.
    Chewaskulyong, B.
    Baranda, L. A. Herraez
    Shearer-Kang, E.
    Liu, X.
    Tosti, N.
    Sanchez, A. Y. Castro
    Zanghi, J.
    Felip, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [42] TWICE-DAILY INTRAVENOUS (IV) BUSULFAN (Bu) X 4 DAYS IN CHILDREN UNDERGOING A REDUCED-INTENSITY CONDITIONING (RIC) REGIMEN WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AlloHSCT) IS SAFE AND WELL-TOLERATED BUT RESULTS IN SIGNIFICANTLY INCREASED Bu CLEARANCE (CL) AND DECREASED AREA UNDER THE CURVE (AUC) AND HALF-LIFE (t1/2) WHEN COMPARED TO IV BU TWICE-DAILY DOSING PHARMACOKINETICS (PK) IN ADULTS
    Waxman, I
    Bhatia, M.
    Milone, M.
    Shaw, L. M.
    Baldinger, L.
    Militano, O.
    Garvin, J.
    George, D.
    Bradley, M. B.
    Satwani, P.
    Schwartz, J.
    Wolownik, K.
    Foley, S.
    Hawks, R.
    Jin, Z. Z.
    Baxter-Lowe, L. A.
    van de Ven, C.
    Cairo, M. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 85 - 85
12345